FluoGuide A/S (FLUO) AI Stock Analysis

FluoGuide A/S

(Nasdaq OMX AB:FLUO)

Select Model

Rating:40Underperform

Price Target:SEK 29.00▼(-4.92% Downside)

Action:downgraded

Date:08/27/26

The overall score of 40 reflects a high-risk, pre-revenue biotechnology company under significant pressure. The most impactful factors are the accelerating cash burn and deteriorating balance sheet, which threaten the company's cash runway. This is compounded by a persistently bearish technical trend with the stock trading below all major moving averages and weak momentum. The negative P/E ratio confirms the lack of current profitability. The slight narrowing of net losses provides minimal relief against these dominant headwinds.

Positive Factors

Positive equity bufferPositive equity and a sizeable asset base provide FluoGuide with some balance-sheet support while it advances development. This buffer does not remove financing needs, but it can help absorb operating losses and preserve flexibility during the clinical-stage period.

Negative Factors

Minimal and declining revenueVery small and declining revenue shows that FluoGuide has not yet established meaningful commercial scale. With the cost base far ahead of current sales, the company remains highly dependent on successful clinical development, regulatory progress, and eventual product adoption.

FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 498.65M
Dividend Yield: ―
Average Volume (3M): 5,323
Price to Earnings (P/E): -6.9
Beta (1Y): 0.18
Revenue Growth: ―
EPS Growth: -23.57%
Country: Sweden
Employees: 7
Sector: General
Sector Strength: 55
Industry: Biotechnology

FluoGuide A/S Business Overview & Revenue Model

Company Description

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade g...

How the Company Makes Money

FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with lar...

FluoGuide A/S Financial Statement Overview

Summary

Pre-revenue biotech with zero meaningful revenue and substantial operating losses (TTM net loss of SEK -46.2M). Cash burn is accelerating (TTM operating cash outflow of SEK -43.8M), equity has nearly halved, and the debt-to-equity ratio has deteriorated to 0.90. The slight narrowing of net losses is the only minor positive, but the overall financial profile is high-risk and entirely dependent on external funding.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	54.00K	0	385.00K	423.00K	6.51M	9.61M
Gross Profit	-416.92K	-571.17K	385.00K	423.00K	6.51M	9.61M
EBITDA	-48.08M	-40.42M	-32.58M	-43.66M	-32.21M	-28.65M
Net Income	-46.24M	-40.39M	-28.96M	-38.38M	-27.34M	-23.77M
Balance Sheet
Total Assets	65.25M	88.34M	28.38M	29.61M	35.62M	53.31M
Cash, Cash Equivalents and Short-Term Investments	49.92M	78.84M	18.61M	21.67M	26.01M	46.76M
Total Debt	27.56M	28.30M	624.00K	10.83M	205.00K	57.00K
Total Liabilities	34.51M	33.78M	5.31M	16.89M	3.65M	14.61M
Stockholders Equity	30.74M	54.56M	23.07M	12.72M	31.97M	38.70M
Cash Flow
Free Cash Flow	-44.28M	-37.83M	-30.00M	-31.81M	-37.71M	-15.06M
Operating Cash Flow	-43.80M	-37.83M	-29.15M	-31.81M	-37.65M	-15.06M
Investing Cash Flow	-30.37M	-30.61M	-987.00K	-37.00K	-117.00K	0
Financing Cash Flow	74.76M	99.33M	27.08M	27.50M	17.02M	51.18M

FluoGuide A/S Technical Analysis

Technical Analysis SentimentNegative

Last Price30.50

Price Trends

50DMA33.20Negative

100DMA34.64Negative

200DMA36.43Negative

Market Momentum

MACD-0.74Negative

RSI43.59Neutral

STOCH55.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 30.50 is below the 20-day moving average (MA) of 31.45, below the 50-day MA of 33.20, and below the 200-day MA of 36.43, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.

FluoGuide A/S Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:FLUO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:FLUI	56Neutral	SEK 38.33M	13.65	21.37%	―	837.37%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:BIOVIC.B	45Neutral	SEK 103.68M	-1.44	-75.51%	―	56.06%	63.95%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:FLUO	40Underperform	SEK 498.65M	-6.94	―	―	―	-23.57%

* General Sector Average

Performance Comparison

SE:FLUO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:FLUO	FluoGuide A/S	30.50	-9.50	-23.75%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:BIOVIC.B	Biovica International AB Class B	0.36	-0.14	-27.47%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%
SE:FLUI	Fluicell AB	27.90	14.90	114.62%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026

FluoGuide A/S AI Stock Analysis